12 Most Profitable Growth Stocks To Invest In

9. Genmab A/S (NASDAQ:GMAB)

5-Year Revenue CAGR: 42.83%

TTM Net Income: $795.6 million

Number of Hedge Fund Holders: 13

Genmab A/S (NASDAQ:GMAB) is a global biotechnology company focused on improving patient outcomes through innovative antibody therapeutics. Over the past 25 years, its dedicated team has developed advanced antibody technology platforms and utilized cutting-edge sciences to build a robust pipeline.

Genmab (NASDAQ:GMAB) has established over 20 partnerships with top biotech and pharmaceutical companies, which improves its capacity to advance novel therapies. In August, the European Commission granted conditional marketing authorization for TEPKINLY (epcoritamab), a subcutaneous bispecific antibody for adults with relapsed or refractory follicular lymphoma.

The approval marks TEPKINLY as the first of its kind, designed to target and eliminate cancerous B-cells and improve the immune system’s response against lymphoma. By 2030, Genmab aims to revolutionize the treatment of cancer and other serious diseases with its groundbreaking antibody medicines.

In July, Genmab (NASDAQ:GMAB) announced that the U.S. FDA has approved EPKINLY (epcoritamab-bysp) for treating adults with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy. This approval makes EPKINLY the first and only subcutaneously administered T-cell engaging bispecific antibody approved for FL in the U.S.

The approval is based on results from the Phase 1/2 EPCORE NHL-1 clinical trial, which showed an 82% overall response rate and a 60% complete response rate in patients with difficult-to-treat FL. EPKINLY is also approved for diffuse large B-cell lymphoma and is seen as a potential key therapy for B-cell malignancies. The company takes the 9th spot on our list of most profitable growth stocks to invest in.